ESTRO 2025 - Abstract Book

S2003

Clinical - Urology

ESTRO 2025

Epic ® 's portal solution MyChart ® enables patients to actively engage in their healthcare by staying connected to providers, accessing their health records, and managing aspects of their care. In addition, patient-reported outcome measures (PROMs) can be assessed using this portal. This study investigates the uptake and usage patterns of MyChart among prostate cancer patients referred for a radiotherapy (RT) consultation, including those who decided against RT following the consultation. MyChart was introduced in the second quarter of 2020, following the adoption of Epic in daily clinical practice in September 2019. We assessed patient participation rates in PROMs collected at key intervals. Material/Methods: Data were collected from consecutive prostate cancer patients referred for an initial consultation, with or without subsequent radiotherapy, between December 2023 and November 2024. All patients were encouraged to complete electronic questionnaires via Epic's MyChart platform at three key time points: before the initial consultation, at the end of RT, and at a first follow-up visit 2 – 8 weeks post-RT. The questionnaires covered the following PROMs: urinary continence evaluated by the International Consultation on Incontinence Questionnaire (ICIQ), urinary and bowel function based on the Expanded Prostate Cancer Index Composite (EPIC-26), and sexual health measured using the International Index of Erectile Function (IIEF). Results: Of the 407 patients assessed in this analysis, 252 (62%) activated their MyChart account (see Figure 1), enabling access to electronic PROM questionnaires during radiotherapy. As illustrated in Figure 2, 116 out of 224 patients (52%) who were provided with the questionnaire before starting RT completed their PROMs; 25 of these 116 patients, and 56 out of the total 224, ultimately did not receive RT. 147 patients who had completed RT to date were invited to participate in the end-of-treatment questionnaire, with a submission rate of 19% (28 patients). In the subsequent post-RT period, 22/83 (27%) patients with a follow-up visit received and completed the questionnaire. These response rates highlight a gradual decrease in engagement across treatment phases, with the highest participation observed prior to RT initiation.